Compugen Ltd. (NASDAQ: CGEN) announced today the development of "NexGen," a new platform designed to significantly enhance Compugen’s overall infrastructure for predictive drug and drug target discovery. NexGen is designed to analyze Next Generation Sequencing data which is now beginning to be generated worldwide through RNA-Seq methodology. RNA-Seq is a new and powerful ultra-high throughput approach to provide raw data for transcriptome analysis and expression profiling. Although this new approach provides a massive amount of data in the form of very short partial transcript sequences, it also creates an extremely challenging environment for obtaining meaningful and accurate information.
Compugen's NexGen Platform, which incorporates advanced algorithms and other proprietary tools, is designed to efficiently and accurately integrate and analyze this vast amount of short sequence data. The integration of this capability with Compugen's discovery infrastructure, mainly its predictive transcriptome and proteome, is expected to provide the Company with both enhanced identification of novel genes and splice variants, and a broader view of the expression levels of RNA transcripts, facilitating new associations to pathological or healthy conditions. These new integrated capabilities should provide Compugen with further substantial advantages in predictive discovery of potential drugs and drug targets, and also in the discovery of potential diagnostic product candidates.
The proprietary insights obtained by Compugen’s decade-long pioneering research focused on predictive transcriptome and expression analysis, which resulted in the Company's LEADS and MED platforms, were fundamental in overcoming the technological challenges in building the NexGen platform. In turn, by enabling the integration and analysis of this enormous quantity of additional data, the NexGen platform adds significant advantages to LEADS and MED, the infrastructure platforms that support all of Compugen’s drug and target product candidate discovery platforms. Similar to the LEADS and MED platforms, NexGen is broadly applicable across essentially all therapeutic and diagnostic areas, but its primary use will be in support of the Company's focus areas of novel therapeutic proteins and monoclonal antibodies for oncology and immunology, highly complex therapeutic areas with significant unmet medical needs.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV